JPWO2021155323A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021155323A5 JPWO2021155323A5 JP2022546341A JP2022546341A JPWO2021155323A5 JP WO2021155323 A5 JPWO2021155323 A5 JP WO2021155323A5 JP 2022546341 A JP2022546341 A JP 2022546341A JP 2022546341 A JP2022546341 A JP 2022546341A JP WO2021155323 A5 JPWO2021155323 A5 JP WO2021155323A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- inventions
- protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 4
- 102000004961 Furin Human genes 0.000 claims description 3
- 108090001126 Furin Proteins 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 208000025721 COVID-19 Diseases 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 241001678559 COVID-19 virus Species 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical group 0.000 description 1
Applications Claiming Priority (43)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969008P | 2020-01-31 | 2020-01-31 | |
| US62/969,008 | 2020-01-31 | ||
| US202062994630P | 2020-03-25 | 2020-03-25 | |
| US62/994,630 | 2020-03-25 | ||
| US202063014467P | 2020-04-23 | 2020-04-23 | |
| US63/014,467 | 2020-04-23 | ||
| US202063025782P | 2020-05-15 | 2020-05-15 | |
| US63/025,782 | 2020-05-15 | ||
| US202062705187P | 2020-06-15 | 2020-06-15 | |
| US62/705,187 | 2020-06-15 | ||
| US202062705308P | 2020-06-21 | 2020-06-21 | |
| US62/705,308 | 2020-06-21 | ||
| US202063043090P | 2020-06-23 | 2020-06-23 | |
| US63/043,090 | 2020-06-23 | ||
| US202062706366P | 2020-08-12 | 2020-08-12 | |
| US62/706,366 | 2020-08-12 | ||
| US202063066147P | 2020-08-14 | 2020-08-14 | |
| US63/066,147 | 2020-08-14 | ||
| US202062706676P | 2020-09-02 | 2020-09-02 | |
| US62/706,676 | 2020-09-02 | ||
| US202062706937P | 2020-09-18 | 2020-09-18 | |
| US62/706,937 | 2020-09-18 | ||
| US202062706958P | 2020-09-21 | 2020-09-21 | |
| US62/706,958 | 2020-09-21 | ||
| US202063198089P | 2020-09-28 | 2020-09-28 | |
| US63/198,089 | 2020-09-28 | ||
| US202063198306P | 2020-10-09 | 2020-10-09 | |
| US63/198,306 | 2020-10-09 | ||
| US202063112900P | 2020-11-12 | 2020-11-12 | |
| US63/112,900 | 2020-11-12 | ||
| CA3101131 | 2020-11-28 | ||
| CA3101131A CA3101131A1 (en) | 2020-01-31 | 2020-11-28 | Compositions and methods for preventing and treating coronavirus infection - sarscov-2 vaccines |
| US202063121482P | 2020-12-04 | 2020-12-04 | |
| US63/121,482 | 2020-12-04 | ||
| US202163133969P | 2021-01-05 | 2021-01-05 | |
| US63/133,969 | 2021-01-05 | ||
| US202163135182P | 2021-01-08 | 2021-01-08 | |
| US63/135,182 | 2021-01-08 | ||
| US202163141913P | 2021-01-26 | 2021-01-26 | |
| US63/141,913 | 2021-01-26 | ||
| US202163142977P | 2021-01-28 | 2021-01-28 | |
| US63/142,977 | 2021-01-28 | ||
| PCT/US2021/015946 WO2021155323A1 (en) | 2020-01-31 | 2021-01-30 | Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512519A JP2023512519A (ja) | 2023-03-27 |
| JP2023512519A5 JP2023512519A5 (https=) | 2024-02-07 |
| JPWO2021155323A5 true JPWO2021155323A5 (https=) | 2024-02-07 |
Family
ID=77079265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546341A Withdrawn JP2023512519A (ja) | 2020-01-31 | 2021-01-30 | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11498944B2 (https=) |
| EP (1) | EP4097122A4 (https=) |
| JP (1) | JP2023512519A (https=) |
| KR (1) | KR20220134622A (https=) |
| CN (1) | CN116096732A (https=) |
| BR (1) | BR112022014808A2 (https=) |
| TW (1) | TW202204380A (https=) |
| UY (1) | UY39060A (https=) |
| WO (1) | WO2021155323A1 (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗 |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| CN115297892A (zh) | 2020-02-07 | 2022-11-04 | 达冕生物有限公司 | 抗新型冠状病毒感染的mRNA疫苗的组合物和方法 |
| WO2021160346A1 (en) * | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| JP2023513611A (ja) | 2020-02-14 | 2023-03-31 | ゲオバックス インコーポレイテッド | Ｓａｒｓ－ｃｏｖ２に対する免疫応答を誘導するためのワクチン及びその利用 |
| CA3167833A1 (en) * | 2020-02-14 | 2021-08-19 | Bertrand Victor Gilbert GEORGES | Coronavirus immunogenic compositions and uses thereof |
| GB2594683A (en) * | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| CN115867349A (zh) | 2020-02-25 | 2023-03-28 | 艾诺奥医药品有限公司 | 针对冠状病毒的疫苗和使用方法 |
| US11213482B1 (en) * | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| EP4143348A4 (en) * | 2020-04-29 | 2024-01-17 | Lu, Shi-Long | VIRAL TEST IN SALIVA |
| US12226431B2 (en) | 2021-09-11 | 2025-02-18 | Porosome Therapeutics, Inc. | Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses |
| JP7788403B2 (ja) | 2020-05-17 | 2025-12-18 | シティ・オブ・ホープ | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
| EP4153311A1 (en) * | 2020-05-20 | 2023-03-29 | Hennrich, Alexandru Adrian | Viral vaccine vector for immunization against a betacoronavirus |
| MX2022015132A (es) * | 2020-05-29 | 2023-03-08 | CureVac SE | Vacunas combinadas a base de acidos nucleicos. |
| EP4157345A4 (en) * | 2020-05-29 | 2024-09-11 | Board of Regents, The University of Texas System | GENETICALLY MODIFIED CORONAVIRUS SPIKE(S) PROTEIN AND METHODS OF USE THEREOF |
| US20230234992A1 (en) * | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| EP4179328A2 (en) * | 2020-07-10 | 2023-05-17 | Covid Diagnostics Ltd. | Compositions, methods, and systems for detecting immune response |
| EP4182687A4 (en) * | 2020-07-20 | 2024-09-11 | Bio-Rad Laboratories, Inc. | IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR |
| CN116157411A (zh) * | 2020-07-31 | 2023-05-23 | 东亚合成株式会社 | SARS-CoV-2衍生氨基酸序列及其应用 |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| US20220193225A1 (en) * | 2020-08-31 | 2022-06-23 | Bruce Lyday | Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| WO2022159433A1 (en) * | 2021-01-20 | 2022-07-28 | Singh Biotechnology, Llc | Therapeutics directed against coronavirus |
| JP7598538B2 (ja) * | 2021-01-29 | 2024-12-12 | 東亞合成株式会社 | ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 |
| BR112023019301A2 (pt) * | 2021-03-22 | 2023-12-05 | Novavax Inc | Formulações de vacina de coronavírus |
| JP2024511463A (ja) | 2021-03-22 | 2024-03-13 | リコード セラピューティクス，インク． | 細胞への標的送達のための組成物および方法 |
| JP2024511437A (ja) | 2021-03-23 | 2024-03-13 | リコード セラピューティクス，インク． | ポリヌクレオチド組成物、関連製剤、およびその使用方法 |
| US20220324918A1 (en) * | 2021-03-30 | 2022-10-13 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF |
| US20220370598A1 (en) * | 2021-05-05 | 2022-11-24 | Inovio Pharmaceuticals, Inc. | Vaccines Against Coronavirus and Methods of Use |
| US20220370600A1 (en) * | 2021-05-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Multigenic mva-sars-cov-2 vaccine |
| WO2023018831A2 (en) | 2021-08-11 | 2023-02-16 | RNAimmune, Inc. | Composition and methods of mrna vaccines against novel coronavirus infection |
| CN113832168B (zh) * | 2021-08-15 | 2023-08-04 | 北京科兴中维生物技术有限公司 | mRNA疫苗及其制备方法和应用 |
| WO2023020939A1 (en) * | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023023940A1 (zh) * | 2021-08-24 | 2023-03-02 | 复旦大学 | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 |
| WO2023026182A1 (en) * | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| CN116041448B (zh) * | 2021-08-26 | 2025-05-13 | 江苏瑞科生物技术股份有限公司 | 新型冠状病毒免疫原性物质、其制备方法和应用 |
| CN113913464B (zh) * | 2021-09-28 | 2022-11-22 | 武汉枢密脑科学技术有限公司 | 一种表达载体、重组腺相关病毒及其在制备2019新型冠状病毒疫苗中的应用 |
| WO2023092100A2 (en) * | 2021-11-19 | 2023-05-25 | Meissa Vaccines, Inc. | Methods of administering chimeric vaccines |
| CN116178527B (zh) * | 2021-11-26 | 2025-12-09 | 深圳先进技术研究院 | 抗sars-cov-2全人源单克隆抗体6g18及其制法与应用 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| KR20240125935A (ko) * | 2021-11-30 | 2024-08-20 | 노바백스, 인코포레이티드 | 코로나바이러스 백신 제형물 |
| TWI843471B (zh) * | 2022-03-11 | 2024-05-21 | 財團法人國家衛生研究院 | 含抗原和dna之組成物及其用途 |
| CN114574502B (zh) * | 2022-04-11 | 2023-07-14 | 四川大学 | 一种以复制缺陷腺相关病毒为载体的新型冠状病毒疫苗 |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| WO2023205589A2 (en) * | 2022-04-20 | 2023-10-26 | Inovio Pharmaceuticals, Inc. | Immunogenic compositions against sars-cov-2 variants and their methods of use |
| WO2023212446A1 (en) * | 2022-04-29 | 2023-11-02 | Xequel Bio, Inc. | Compositions and methods for treating complications of viral infections and other respiratory disorders |
| WO2023240278A2 (en) * | 2022-06-10 | 2023-12-14 | The Trustees Of Columbia University In The City Of New York | Uses of glycolipids as a vaccine adjuvant and methods thereof |
| US11654121B1 (en) | 2022-06-22 | 2023-05-23 | Flagship Pioneering Innovations Vi, Llc | Combination therapies for the treatment of viral infections |
| US20250228814A1 (en) | 2022-06-22 | 2025-07-17 | Flagship Pioneering Innovations Vi, Llc | Combination therapies for the treatment of viral infections |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CA3261388A1 (en) * | 2022-07-07 | 2025-04-24 | Westvac Biopharma Co., Ltd. | Pharmaceutical composition to resist SARS-CoV-2 infection or a mutation thereof and a combination drug thereof |
| WO2024032468A1 (zh) * | 2022-08-08 | 2024-02-15 | 神州细胞工程有限公司 | 一种可诱导广谱中和活性重组五组分新冠病毒三聚体蛋白疫苗的制备及应用 |
| EP4599056A2 (en) * | 2022-10-07 | 2025-08-13 | Zeptometrix LLC | Control for protein-based assay |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| US12280104B2 (en) | 2022-11-01 | 2025-04-22 | RNAimmune, Inc. | Composition and methods for MRNA vaccines against novel omicron coronavirus infections |
| CN116024269B (zh) * | 2022-11-18 | 2024-02-02 | 复百澳(苏州)生物医药科技有限公司 | 一种冠状病毒假病毒颗粒的制备方法 |
| CN116077635B (zh) * | 2022-11-23 | 2026-03-20 | 珠海市丽珠单抗生物技术有限公司 | 新型冠状病毒融合蛋白疫苗其应用 |
| CN116585465B (zh) * | 2023-04-19 | 2025-12-30 | 山东兴瑞生物科技有限公司 | 一种雾化吸入新冠疫苗及其制备方法 |
| EP4704880A1 (en) * | 2023-05-03 | 2026-03-11 | Partner Therapeutics, Inc. | Viral infection modulation in vaccinated subjects treated with granulocyte-macrophage colony-stimulating factor (gm-csf) |
| EP4704881A2 (en) * | 2023-05-03 | 2026-03-11 | Partner Therapeutics, Inc. | Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf) |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| DE69233158T2 (de) | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| KR100912362B1 (ko) | 1998-02-17 | 2009-08-19 | 쉐링 코포레이션 | 바이러스 제제의 정제방법 |
| DE69940354D1 (de) | 1998-11-16 | 2009-03-12 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| ES2284545T3 (es) | 1999-11-16 | 2007-11-16 | Genzyme Corporation | Vectores y transgenes con elementos reguladores para la administracion de genes del higado. |
| EP2420247A1 (en) | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| ATE437221T1 (de) | 2001-05-14 | 2009-08-15 | Gbp Ip Llc | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie |
| EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
| AR038153A1 (es) | 2002-01-18 | 2004-12-29 | Schering Ag | Formulaciones estabilizadas de adenovirus |
| US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| WO2005005596A2 (en) | 2003-06-18 | 2005-01-20 | Chinese National Human Genome Center At Shanghai | Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| CA2531684C (en) | 2003-07-22 | 2014-03-11 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
| US20070270361A1 (en) * | 2003-08-04 | 2007-11-22 | Shan Lu | Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof |
| US7129042B2 (en) * | 2003-11-03 | 2006-10-31 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting severe acute respiratory syndrome coronavirus |
| US20070116716A1 (en) * | 2003-12-10 | 2007-05-24 | Shuo Shen | Sars coronavirus s proteins and uses thereof |
| ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| BRPI0516048A (pt) | 2004-10-13 | 2008-08-19 | Crucell Holland B V E Beth Isr | batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c |
| CN101068575A (zh) | 2004-12-01 | 2007-11-07 | 建新公司 | 向肝脏定向递送遗传物质的方法 |
| CN101969996A (zh) | 2005-08-23 | 2011-02-09 | 加利福尼亚大学董事会 | 多价疫苗 |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| US20090110695A1 (en) | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| CN102203242B (zh) | 2008-11-03 | 2013-06-12 | 克鲁塞尔荷兰公司 | 产生腺病毒载体的方法 |
| WO2010059732A1 (en) | 2008-11-18 | 2010-05-27 | Beth Israel Deaconess Medical Center | Antiviral vaccines with improved cellular immunogenicity |
| EP2391638B1 (en) | 2009-02-02 | 2018-06-27 | GlaxoSmithKline Biologicals SA | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
| DK2655604T3 (en) | 2010-12-14 | 2018-08-06 | Us Gov Health & Human Services | ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| EA026504B1 (ru) * | 2012-03-22 | 2017-04-28 | Круселл Холланд Б.В. | Вакцина против rsv |
| EP4599847A3 (en) * | 2016-10-25 | 2025-11-12 | Trustees of Dartmouth College | Prefusion coronavirus spike proteins and their use |
| CN110268061B (zh) | 2017-02-09 | 2024-07-16 | 扬森疫苗与预防公司 | 用于表达异源基因的有效的短启动子 |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| GB201708444D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
| MA50502A (fr) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention Bv | Adénovirus et utilisations associées |
| BR112020008435A2 (pt) | 2017-10-31 | 2020-11-17 | Janssen Vaccines & Prevention B.V. | vetores de adenovírus e seus usos |
| WO2019086466A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| RU2709659C1 (ru) * | 2018-09-06 | 2019-12-19 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты) |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| JP2023511633A (ja) * | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスｒｎａワクチン |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗 |
| WO2021229450A1 (en) * | 2020-05-11 | 2021-11-18 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| US10906944B2 (en) | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
-
2021
- 2021-01-30 TW TW110103610A patent/TW202204380A/zh unknown
- 2021-01-30 BR BR112022014808A patent/BR112022014808A2/pt not_active IP Right Cessation
- 2021-01-30 WO PCT/US2021/015946 patent/WO2021155323A1/en not_active Ceased
- 2021-01-30 EP EP21747489.9A patent/EP4097122A4/en not_active Withdrawn
- 2021-01-30 CN CN202180025856.2A patent/CN116096732A/zh active Pending
- 2021-01-30 JP JP2022546341A patent/JP2023512519A/ja not_active Withdrawn
- 2021-01-30 US US17/163,357 patent/US11498944B2/en active Active
- 2021-01-30 US US17/759,803 patent/US20230075527A1/en not_active Abandoned
- 2021-01-30 KR KR1020227030114A patent/KR20220134622A/ko not_active Withdrawn
- 2021-02-01 UY UY0001039060A patent/UY39060A/es unknown
- 2021-07-28 US US17/387,105 patent/US11384122B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021155323A5 (https=) | ||
| US20230381301A1 (en) | Respiratory virus nucleic acid vaccines | |
| JP2025084808A (ja) | エプスタイン－バーウイルスワクチン | |
| US10059747B2 (en) | Crimean-congo haemorrhagic fever virus antigenic composition | |
| CN116059336A (zh) | 针对rsv的疫苗 | |
| US6235888B1 (en) | Hepatitis C virus vaccine | |
| EA007154B1 (ru) | Слитый белок из числа регуляторных/вспомогательных белков вич | |
| US20250000968A1 (en) | Sars-cov-2 spike fused to a hepatitis b surface antigen | |
| US20240002462A1 (en) | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs | |
| BR112021013874A2 (pt) | Composição de ácido nucleico, vetor de terapia de gene de mamífero, partícula de vírus adeno-associado, métodos para tratar hemofilia a e para produzir uma partícula de vírus adeno-associado, e, uso de uma composição de ácido nucleico e de um vetor de terapia de gene de mamífero | |
| WO2021042944A1 (zh) | 肌肉靶向的微环dna基因治疗 | |
| JP2004501650A5 (https=) | ||
| JP2025084850A (ja) | ハンタウイルス抗原性組成物 | |
| AU2018383915B9 (en) | Multivalent feline vaccine | |
| KR101756131B1 (ko) | 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물 | |
| AU2018371355B2 (en) | Synthetic hemagglutinin as universal vaccine against infection by type B influenza viruses (IBV) | |
| CN110382518B (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| US11730809B2 (en) | Multivalent feline vaccine | |
| EP3706790A1 (en) | Multivalent feline vaccine | |
| WO2023047349A1 (en) | Stabilized coronavirus spike protein fusion proteins | |
| WO2025180455A1 (en) | A circular rna vaccine against herpes zoster virus and the use thereof | |
| JPWO2023150638A5 (https=) | ||
| US20250049912A1 (en) | Multicistronic Vaccine and Methods for Producing and Using the Same | |
| WO2024061759A1 (en) | Stabilized coronavirus s proteins | |
| EP4282429A1 (en) | Multivalent covid-19 vaccines based on adenoviral vectors |